RedHill Biopharma Ltd. (RDHL)
NASDAQ: RDHL · Real-Time Price · USD
6.50
+0.03 (0.46%)
At close: Dec 20, 2024, 4:00 PM
6.69
+0.19 (2.92%)
After-hours: Dec 20, 2024, 4:01 PM EST
RedHill Biopharma Employees
RedHill Biopharma had 53 employees as of December 31, 2023. The number of employees decreased by 60 or -53.10% compared to the previous year.
Employees
53
Change (1Y)
-60
Growth (1Y)
-53.10%
Revenue / Employee
$69,943
Profits / Employee
-$569,321
Market Cap
8.32M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Meihua International Medical Technologies | 617 |
Viracta Therapeutics | 40 |
Dominari Holdings | 28 |
NeuroMetrix | 26 |
BioCardia | 20 |
Virax Biolabs Group | 17 |
QT Imaging Holdings | 14 |
COSCIENS Biopharma | 12 |
RDHL News
- 11 days ago - Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development - PRNewsWire
- 19 days ago - RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court - PRNewsWire
- 7 weeks ago - RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND - PRNewsWire
- 2 months ago - RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury - PRNewsWire
- 2 months ago - RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment - PRNewsWire
- 2 months ago - RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians - PRNewsWire
- 2 months ago - RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041 - PRNewsWire
- 3 months ago - RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines - PRNewsWire